def14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check the appropriate box:
o |
|
Preliminary Proxy Statement |
|
o |
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
þ |
|
Definitive Proxy Statement |
|
o |
|
Definitive Additional Materials |
|
o |
|
Soliciting Material Pursuant to §240.14a-12 |
Synergetics USA, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
þ |
|
No fee required. |
|
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies: |
|
|
|
|
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies: |
|
|
|
|
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was
determined): |
|
|
|
|
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction: |
|
|
|
|
|
|
|
(5) |
|
Total fee paid: |
|
|
|
|
|
o |
|
Fee paid previously with preliminary materials. |
|
o |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and
identify the filing for which the offsetting fee was paid previously. Identify the previous filing
by registration statement number, or the Form or Schedule and the date of its filing. |
|
(1) |
|
Amount Previously Paid: |
|
|
|
|
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.: |
|
|
|
|
|
|
|
(3) |
|
Filing Party: |
|
|
|
|
|
|
|
(4) |
|
Date Filed: |
|
|
|
|
|
|
|
|
Persons who are to respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB control number. |
SYNERGETICS
USA, INC.
3845
Corporate Centre Drive
OFallon, Missouri 63368
November 24, 2009
Dear Stockholder:
You are cordially invited to attend our Companys 2009
Annual Meeting of Stockholders, which will be held on
December 17, 2009, at 6:00 p.m., Central Time, at The
Doubletree Hotel and Conference Center located at 16625 Swingley
Ridge Road, Chesterfield, Missouri 63017. The formal Notice of
Annual Meeting of Stockholders and Proxy Statement accompanying
this letter describe the business to be acted upon at the
meeting.
Your vote is important to us and your shares should be
represented at the meeting whether or not you are personally
able to attend. Accordingly, I encourage you to mark, sign, date
and return the accompanying proxy promptly.
On behalf of the Board of Directors, thank you for your
continued support of Synergetics USA, Inc.
Sincerely,
David M. Hable
President and Chief Executive Officer
TABLE OF CONTENTS
SYNERGETICS
USA, INC.
NOTICE
OF ANNUAL MEETING OF STOCKHOLDERS
To Be Held on December 17, 2009
NOTICE IS HEREBY GIVEN that the 2009 Annual Meeting of
Stockholders of Synergetics USA, Inc., a Delaware corporation
(the Company), will be held on December 17,
2009, at 6:00 p.m., Central Time, at The Doubletree Hotel
and Conference Center located at 16625 Swingley Ridge Road,
Chesterfield, Missouri 63017 to act upon the following matters,
which are described more fully in the accompanying Proxy
Statement:
1. The election of two directors nominated by the
Companys Nominating and Governance Committee to serve
three year terms following approval by the stockholders at the
Annual Meeting;
2. The ratification of the appointment of the
Companys independent registered public accounting firm for
fiscal 2010, UHY LLP (UHY); and
3. Such other business as may properly come before the
meeting
and/or any
adjournment thereof.
All holders of common stock of record at the close of business
on November 17, 2009 are entitled to notice of, and to vote
at, the Annual Meeting or any adjournment thereof.
The Board of Directors of the Company has authorized the
solicitation of proxies. Unless otherwise directed, the proxies
will be voted FOR the election of the nominees listed in the
attached Proxy Statement to be members of the Board of Directors
of the Company, FOR ratification of UHYs appointment and
on other business that may properly come before the Annual
Meeting, as the named proxies in their best judgment shall
decide.
Any stockholder submitting a proxy may revoke such proxy at any
time prior to its exercise by notifying the Secretary of the
Company in writing at 3845 Corporate Centre Drive,
OFallon, Missouri, 63368 prior to the Annual Meeting, and,
if you attend the Annual Meeting, you may revoke your proxy if
previously submitted and vote in person by notifying the
Secretary of the Company at the Annual Meeting.
This Notice of Annual Meeting and the Proxy Statement and the
form of proxy are being distributed on or about
November 24, 2009.
Your vote is very important. Whether or not you plan to attend
the Annual Meeting, we encourage you to read the Proxy Statement
and submit your proxy as soon as possible. You may submit your
proxy for the Annual Meeting by completing, signing, dating and
returning your proxy in the pre-addressed envelope provided.
By Order of the Board of Directors,
PAMELA G. BOONE, Secretary
OFallon, Missouri
November 24, 2009
SYNERGETICS
USA, INC.
FOR
THE 2009 ANNUAL MEETING OF STOCKHOLDERS
Important
Notice Regarding the Availability of Proxy Materials for the
Annual Stockholders Meeting To Be Held on December 17,
2009
The proxy statement and annual report to stockholders for the
fiscal year ended July 31, 2009 are available at
http://www.amstock.com/ProxyServices/ViewMaterial.asp?CoNumber=06536.
GENERAL
INFORMATION
This Proxy Statement is being furnished in connection with the
solicitation of proxies by the Board of Directors of Synergetics
USA, Inc., a Delaware corporation (the Company),
3845 Corporate Centre Drive, OFallon, Missouri, 63368, for
use at the 2009 Annual Meeting of Stockholders to be held on
December 17, 2009, at 6:00 p.m. Central Time at
The Doubletree Hotel and Conference Center located at 16625
Swingley Ridge Road, Chesterfield, Missouri 63017. The Board of
Directors of the Company urges you to promptly execute and
return your proxy in the enclosed envelope, even if you plan on
attending the Annual Meeting. This is designed to authenticate
stockholders identities, to allow stockholders to give
their voting instructions and to confirm that stockholders
instructions have been recorded properly.
Any stockholder submitting a proxy may revoke such proxy at any
time prior to its exercise by notifying the Secretary of the
Company, in writing, prior to the Annual Meeting. Any
stockholder attending the Annual Meeting may revoke his or her
proxy and vote personally by notifying the Secretary of the
Company at the Annual Meeting. For additional information on how
to obtain directions to be able to attend the meeting and vote
in person, please write to the Companys Secretary at
Synergetics USA, Inc., 3845 Corporate Centre Drive,
OFallon, Missouri 63368 or call
(636) 939-5100.
Only stockholders of record at the close of business on
November 17, 2009, will be entitled to notice of, and to
vote at, the Annual Meeting or any adjournment thereof. At the
close of business on November 17, 2009, the Company had
24,492,554 outstanding shares of common stock, $0.001 par
value per share (the Common Stock). Each share of
Common Stock entitles the holder thereof to one vote.
If the accompanying proxy card is signed and returned, the
shares represented thereby will be voted in accordance with the
directions on the proxy card. Unless a stockholder specifies
otherwise therein, the proxy will be voted in accordance with
the recommendations of the Board of Directors on all proposals.
The presence in person or by proxy of a majority of the voting
power represented by outstanding shares of Common Stock will
constitute a quorum for the transaction of business at the
Annual Meeting.
Directors will be elected by a plurality of the voting power
represented and entitled to vote at the meeting. The passage of
any other proposal will be determined by the affirmative vote of
the majority of the voting power represented and entitled to
vote at the meeting. In the election of directors, abstentions
and broker non-votes will not affect the outcome except in
determining the presence of a quorum; they will not be counted
toward the number of votes required for any nominees
election. An instruction to abstain from voting on
any other proposal will have the same effect as a vote against
the proposal. Currently, broker non-votes will not be considered
as present and entitled to vote on the proposals; therefore,
broker non-votes will have no effect on the number of
affirmative votes required to adopt such proposal.
This Proxy Statement and the enclosed proxy card are being
mailed to the stockholders of the Company on or about
November 24, 2009.
PROPOSAL 1
ELECTION OF DIRECTORS
The Companys Amended and Restated Bylaws provide that the
Board shall consist of not less than five nor more than 11
members, the exact number of which shall be determined by the
Board. The number of directors on the Companys Board of
Directors is currently set at seven directors, divided into
three classes with each class serving three-year staggered terms.
The terms of Robert H. Dick and Juanita H. Hinshaw expire at the
2009 Annual Meeting. Mr. Dick and Ms. Hinshaw have
been nominated for re-election. The Board of Directors of the
Company recommends a vote FOR the two nominees. If re-elected,
each nominee will serve until the annual election of directors
in the year 2012 or until his or her successor is duly elected
and qualified, or his or her earlier death, resignation or
removal. If any of the nominees are unavailable for election, an
event which the Board of Directors of the Company does not
presently anticipate, the persons named in the enclosed proxy
intend to vote the proxies solicited hereby FOR the election of
such other nominee or nominees as may be nominated by the Board
of Directors.
Based on the recommendation of the Nominating and Corporate
Governance Committee, both of the nominees have been approved
unanimously by the Board of Directors of the Company for
re-election. Set forth below is information concerning the two
nominees for director and the directors whose terms are
continuing.
Nominees
for Directors to be Re-Elected at the 2009 Annual Meeting for
Terms expiring in 2012
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Age
|
|
|
Biography
|
|
|
|
|
Robert H. Dick
|
|
|
66
|
|
|
Robert H. Dick has been a director of the Company since 2005,
when Synergetics, Inc. merged with Valley Forge Scientific Corp.
(Valley Forge) (now known as Synergetics USA, Inc.
or the Company) and currently serves as the Chairman
of the Board of Directors. He has served as Chairman of the
Board of Directors since July 31, 2008. From July 31,
2008 until January 28, 2009, Mr. Dick, along with the
Companys other independent directors, served as the
Companys principal executive officer, generally on a
weekly rotating basis. Prior to the merger, Mr. Dick had
been a director of Valley Forge since 1997. Mr. Dick has
served as President of R.H. Dick & Company since
January 1998, a consulting firm based in Camp Verde, Texas. From
1996 to 1998, he was a partner with Boles, Knop &
Company, Inc., an investment banking firm in Middleburg,
Virginia. From 1994 to 1996, Mr. Dick served as interim
President, Chief Executive Officer and Chief Financial Officer
of two of Boles clients. From 1982 until 1994, he served
in various executive roles with Codman & Shurtleff,
Inc., a subsidiary of Johnson & Johnson and a
manufacturer of surgical instruments, implants, equipment and
other surgical products. From 1978 to 1982, Mr. Dick was
President and Chief Executive Officer of Applied Fiberoptics,
Inc., a company designing, manufacturing and marketing
fiberoptic products for medical and defense applications, and
surgical microscopes for microsurgery. From 1969 to 1978,
Mr. Dick held various sales, marketing and general
management positions with the USCI division of C.R. Bard, Inc.
Mr. Dick also serves as a member of the board, chairman of
the audit committee and member of the executive and governance
committees for
Span-America
Medical Systems, Inc., which designs and manufactures wound
management products and which has securities registered pursuant
to Section 12 of the Securities and Exchange Act of 1934
(the Exchange Act).
|
|
|
2012
|
|
2
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Age
|
|
|
Biography
|
|
|
|
|
Juanita H. Hinshaw
|
|
|
64
|
|
|
Juanita H. Hinshaw has served as a director of the Company since
2005 when Synergetics, Inc. merged with Valley Forge. From
July 31, 2008 until January 28, 2009,
Ms. Hinshaw, along with the Companys other
independent directors, served as the Companys principal
executive officer, generally on a weekly rotating basis.
Ms. Hinshaw has been President and Chief Executive Officer
of H&H Advisors (a financial advisory company) since 2005.
In addition, Ms. Hinshaw served as Senior Vice President
and Chief Financial Officer of Graybar Electric Company from May
2000 to May 2005. Graybar Electric Company specializes in supply
chain management services and distributes high-quality
components, equipment and materials for the electrical and
telecommunications industries. Ms. Hinshaw has served as a
director, chairman of the finance committee and as a member of
the audit committee for The Williams Companies, Inc. since 2004
and has served as a director on the board, chairman of the
compensation committee and as a member of the audit committee
for Insituform Technologies, Inc. since 1999. The Williams
Company and Insituform Technologies, Inc. have securities
registered pursuant to Section 12 of the Exchange Act.
|
|
|
2012
|
|
Directors
whose Terms Continue beyond the 2009 Annual
Meeting
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
|
Name
|
|
Age
|
|
|
Principal Occupation and Other Information
|
|
of Term
|
|
|
Lawrence C. Cardinale
|
|
|
71
|
|
|
Lawrence C. Cardinale has served as a director of the Company
since 2005. From July 31, 2008 until January 28, 2009,
Mr. Cardinale, along with the Companys other
independent directors, served as the Companys principal
executive officer, generally on a weekly rotating basis.
Mr. Cardinale received his B.S.B.A. in Business from
Washington University in St. Louis, Missouri and is retired
after working in the medical industry since 1966. During his
over 35 years working in the field of medical
manufacturing, he held various management positions, including
Plant Manager, Director of Manufacturing, Director of Corporate
Engineering, Director of Operations Planning, Vice President of
Manufacturing-International and Vice President-Global
Manufacturing and Engineering of a multi-national medical
manufacturing company. Mr. Cardinale also owned and
operated a scientific laboratory instrument business
concentrating in the life sciences area, which manufactured and
marketed tissue sectioning, microforge and micromanipulation
instruments and pipeting devices. Mr. Cardinale formerly
served as a board member of Coretech-Holdings LLC, a
St. Louis-based life sciences and medical device
manufacturing company, and McCormick Scientific, LLC.
|
|
|
2010
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
|
Name
|
|
Age
|
|
|
Principal Occupation and Other Information
|
|
of Term
|
|
|
Guy R. Guarch
|
|
|
69
|
|
|
Guy R. Guarch has been a director of the Company since 2005,
when Synergetics, Inc. merged with Valley Forge. From
July 31, 2008 until January 28, 2009, Mr. Guarch,
along with the Companys other independent directors,
served as the Companys principal executive officer,
generally on a weekly rotating basis. Mr. Guarch retired in
2001 from C.R. Bard, Inc. where he spent 32 years in
various sales, marketing and management roles. Bard is a leading
developer, manufacturer and marketer of health care products
used for vascular, urological and onocological diagnosis and
intervention. From 1993 to 2001, Mr. Guarch served as
Regional Vice President Corporate Account Manager for
Bards Southeast Region. He worked as President of Bard
Venture Division in Boston, Massachusetts from 1991 to 1993.
From 1988 to 1991, Mr. Guarch worked in London, England, as
Vice President of Sales for the Bard European Division and
Managing Director of Bard LTD, UK. Before 1988, Mr. Guarch
worked in several sales and marketing roles for Bards USCI
International Division in Boston, Massachusetts, which focused
on the design, manufacture and sale of cardiac catheters,
urological catheters and artificial arteries. Mr. Guarch
currently serves as a board member and chairman of the
governance committee for
Span-America
Medical Systems, Inc., which designs and manufactures wound
management products and which has securities registered pursuant
to Section 12 of the Exchange Act.
|
|
|
2010
|
|
|
|
|
|
|
|
|
|
|
|
|
David M. Hable
|
|
|
54
|
|
|
David M. Hable joined the Company as its President, CEO and
director in January 2009. Prior to joining the Company,
Mr. Hable served as President and CEO of Afferent
Corporation, a venture capital backed medical device company
focused on neuro stimulation therapies. Previously, he was
Chairman of the Board of ONI Medical Systems, Inc., a developer
and marketer of magnetic resonance imaging equipment for
extremity applications in non-hospital settings. Mr. Hable
also spent over 20 years with Johnson & Johnson
working in business units that developed and marketed a wide
range of diagnostic and therapeutic products for the treatment
of central nervous system disorders. From 1998 to 2003,
Mr. Hable served as Codman & Shurtleffs
Worldwide President, leading all functions in the company, both
domestically and internationally. Mr. Hable had overall
responsibility for the management of the Company.
|
|
|
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
Kurt W. Gampp, Jr.
|
|
|
49
|
|
|
Kurt W. Gampp, Jr. is the Companys Executive Vice
President and Chief Operating Officer and has served in these
positions and as a director since 2005 when Synergetics, Inc.
merged with Valley Forge. Immediately prior to the merger with
Valley Forge, Mr. Gampp served as the Executive Vice
President and Chief Operating Officer of Synergetics, Inc. and
had served in this position since Synergetics, Inc. was founded
in 1991. Mr. Gampp coordinates and supervises the
manufacturing of the Companys products and is in charge of
the daily production operations of the Company.
|
|
|
2011
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expiration
|
|
Name
|
|
Age
|
|
|
Principal Occupation and Other Information
|
|
of Term
|
|
|
Jerry L. Malis
|
|
|
77
|
|
|
Jerry L. Malis is the Companys Executive Vice President
and Chief Scientific Officer and has served in these positions
and as a director since 2005. Immediately prior to the
consummation of the merger with Valley Forge, Dr. Malis
served as Valley Forges Chief Executive Officer, President
and Chairman of the Board of Valley Forge. He has published over
50 articles in the biological science, electronics and
engineering fields, and has been issued ten United States
patents. Dr. Malis coordinates and supervises the
scientific developments of the Company.
|
|
|
2011
|
|
CORPORATE
GOVERNANCE
The Companys Board of Directors met twelve times during
the fiscal year ended July 31, 2009, eight of which were
special meetings. Each of our directors attended at least 75% of
all the meetings of the Board and those committees on which he
or she served during fiscal year 2009 either in person or
telephonically. The Board of Directors encourages all members to
attend stockholder meetings, but has not adopted a formal policy
regarding attendance. All of the Companys directors
attended last years annual stockholders meeting.
The Board of Directors has determined that each of the directors
other than Messrs. Hable, Gampp and Malis satisfies the
definition of an independent director set forth in the listing
standards of The NASDAQ Stock Market, Inc. (Nasdaq)
and the Companys Corporate Governance Guidelines,
available on the Companys website at
www.synergeticsusa.com. In addition, the Board of
Directors has determined that each of the members of the Audit
Committee satisfies the additional conditions for independence
for Audit Committee members required by Nasdaq.
The Companys Corporate Governance Guidelines also state
that the independent directors should meet each time that a
regularly scheduled Board meeting is held, in addition to
holding other meetings as needed. During fiscal 2009, the
independent directors held four meetings in conjunction with
regularly scheduled Board meetings and four special meetings.
The Board of Directors maintains the following three standing
committees: an Audit Committee, a Compensation Committee and a
Nominating and Corporate Governance Committee. Each of these
committees operates pursuant to a written charter setting forth
the functions and responsibilities of the committee, which may
be reviewed on our website at www.synergeticsusa.com and
are also available to stockholders in print upon request.
Audit
Committee
The Audit Committee is responsible for the appointment,
evaluation, compensation and oversight of the work of the
independent registered public accounting firm and, where
appropriate, the dismissal of the independent registered public
accounting firm. Furthermore, the Audit Committee is responsible
for meeting with the independent registered public accounting
firm and other corporate officers to review matters relating to
financial reporting and accounting procedures and policies.
Among other responsibilities, the Audit Committee also reviews
financial information provided to stockholders and others,
assesses the adequacy of financial, accounting, operating and
disclosure controls, evaluates the scope of the audits of the
independent registered public accounting firm and internal
auditors, and reports on the results of such audits to the Board
of Directors. The current members of the Audit Committee are
Ms. Hinshaw (Chairperson), Mr. Dick, and
Mr. Cardinale, all of whom meet all applicable standards
for Audit Committee membership under the Nasdaq listing
standards and Securities and Exchange Commission
(SEC) rules. The Audit Committee held four meetings
during the last fiscal year.
Compensation
Committee
The Compensation Committee is composed entirely of independent
directors, as defined by the Nasdaq listing standards and SEC
rules, and is responsible for administering the Companys
compensation programs and recommending to the Board of Directors
other compensation and benefits of the Chief Executive Officer
and all named executive officers. The current members of the
Compensation Committee are Mr. Dick (Chairperson),
Mr. Cardinale and Mr. Guarch, all of whom meet the
independence requirements of the Nasdaq listing standards and
SEC rules. The Compensation Committee held four meetings during
the last fiscal year.
5
The Compensation Committee meets at the end of each fiscal year
to determine and recommend to the Board for approval the
compensation packages for executive officers in light of the
Companys compensation philosophy and objectives. The
Compensation Committee considers recommendations from the Chief
Executive Officer as to compensation for each executive officer
based upon their performance against Company and personal
objectives, other than himself. The Compensation Committee has
full responsibility to recommend to the independent directors of
the Board the compensation package of the Chief Executive
Officer. The Compensation Committee may not delegate its
authority regarding executive compensation.
Nominating
and Corporate Governance Committee
The members of the Companys Nominating and Corporate
Governance Committee are Mr. Cardinale (Chairperson),
Mr. Dick and Mr. Guarch, all of whom meet the
independence requirements of the Nasdaq listing standards and
SEC rules. The Nominating and Corporate Governance Committee is
responsible for identifying individuals qualified to become
members of the Board of Directors, recommending to the Board of
Directors the director nominees to be proposed for election by
the stockholders and recommending to the Board of Directors
corporate governance guidelines and procedures applicable to the
Company. The Nominating and Corporate Governance Committee held
four meetings during the last fiscal year.
The Nominating and Corporate Governance Committee will consider
director nominees recommended by stockholders of the Company.
Each stockholder must comply with applicable requirements of the
Companys Amended and Restated Bylaws and the Exchange Act
with respect to the nomination of, or proposal of, nominees for
election as directors of the Company. Stockholders should submit
any such nominations, together with appropriate biographical
information and a description of the nominees
qualifications to serve as director, to the Chairperson of the
Nominating and Corporate Governance Committee,
c/o Pamela
G. Boone, Secretary, Synergetics USA, Inc., 3845 Corporate
Centre Drive, OFallon, Missouri 63368. The Companys
Corporate Governance Guidelines do not require that qualified
director candidates should be limited by specific selection
criteria. Candidates are selected for, among other things, their
independence, integrity, diverse experience, leadership ability,
ability to exercise sound judgment, scientific expertise,
experience at policy-making levels involving issues affecting
business, government, education and technology, and experience
relevant to the Companys global medical device
microsurgery business. Final approval of a candidate is
determined by the full Board of Directors. Nominees to be
evaluated by the Nominating and Corporate Governance Committee
for future vacancies on the Board of Directors will be selected
by the Nominating and Corporate Governance Committee from
candidates recommended by multiple sources, including members of
the Board of Directors, senior management, independent search
firms, stockholders and other sources, all of whom will be
evaluated based on the same criteria.
Code
of Conduct and Ethics
The Company has established a Code of Business Conduct and
Ethics, which is applicable to all of its employees, officers
and directors. The Code is available on the Companys
website at www.synergeticsusa.com and also available to
stockholders in print upon request. We intend to post any future
amendments and revisions to the Code of Business Conduct and
Ethics on our website.
COMMUNICATIONS
WITH THE BOARD OF DIRECTORS
Stockholders may communicate directly with the Board of
Directors, as a group, or any individual director by submitting
written correspondence addressed to the Board or an individual
director at Synergetics USA, Inc., 3845 Corporate Centre Drive,
OFallon, Missouri 63368. All communications are relayed
onto the appropriate Board member or members.
DIRECTOR
COMPENSATION
Directors who are neither employees of the Company nor an
immediate family member of an officer of the Company are paid
$750 for each meeting of the Board of Directors and each meeting
of a committee of the Board of Directors that they attend. The
Chairperson of the Audit Committee receives $2,250 for each
meeting of the Audit Committee. All directors are entitled to
reimbursement for travel and lodging expenses incurred in
connection with their attendance at meetings. In addition, the
independent directors receive compensation at the standard Board
meeting rate of $750 per day for each day spent at the Company
and each day spent away from personal business on
6
Company business. In addition, the independent directors receive
$500 per meeting for each telephonic meeting of the independent
directors or on Company business. This additional compensation
arrangement has been approved by the management directors.
Directors who are also employees of the Company do not receive
compensation for their services as members of the Board of
Directors.
Compensation for members of the Board has been established and
will be reviewed annually by the Compensation Committee. The
Compensation Committee may not delegate its authority regarding
director compensation, and no executive officer plays a role in
determining the amount of director compensation. The
Compensation Committee considers the amount of time directors
dedicate to Company matters and the need to attract and retain
qualified directors when determining Board compensation. For
example, the Compensation Committee has approved additional
compensation for the Audit Committee Chairperson in recognition
of the time commitment required by such position.
To align the interests of directors with those of the
Companys stockholders, each independent director also
receives an option to purchase 10,000 shares of the
Companys Common Stock each year in which he or she is
elected, appointed, or re-elected to serve as a director
pursuant to the Amended and Restated 2005 Non-Employee
Directors Stock Option Plan.
As previously disclosed, Gregg Scheller resigned as Chief
Executive Officer of the Company effective July 31, 2008.
Until David Hable was hired as the Companys new Chief
Executive Officer on January 28, 2009, each of our
independent directors served as principal executive officer of
the Company on a weekly rotating basis. As such, all
compensation received by the independent directors in all
capacities during the fiscal year ended July 31, 2009 is
included in the Summary Compensation Table.
PRINCIPAL
STOCKHOLDERS
The following table sets forth as of November 17, 2009
certain information with respect to the beneficial ownership of
the Companys Common Stock by (i) each of the named
executive officers and directors, (ii) all executive
officers and directors as a group, and (iii) each person
known by the Company to beneficially own more than 5% of the
Companys Common Stock based on certain filings made under
Section 13 of the Exchange Act. All such information
provided by the stockholders who are not executive officers or
directors reflects their beneficial ownership as of the dates
specified in the relevant footnotes to the table. The percent of
shares beneficially owned is based on 24,492,554 shares
issued and outstanding as of November 17, 2009.
|
|
|
|
|
|
|
|
|
|
|
Amount and
|
|
Percent of
|
|
|
Nature of
|
|
Shares
|
|
|
Beneficial
|
|
Beneficially
|
Name and Address of Beneficial Owner
|
|
Ownership
|
|
Owned
|
|
(i) Named Executive Officers and Directors(1)
|
|
|
|
|
|
|
|
|
David M. Hable
|
|
|
16,000
|
(2)
|
|
|
*
|
|
Lawrence C. Cardinale
|
|
|
64,244
|
(3)
|
|
|
*
|
|
Robert H. Dick
|
|
|
103,000
|
(4)
|
|
|
*
|
|
Kurt W. Gampp, Jr.
|
|
|
869,842
|
(5)
|
|
|
3.6
|
%
|
Guy R. Guarch
|
|
|
44,000
|
(6)
|
|
|
*
|
|
Juanita H. Hinshaw
|
|
|
366,710
|
(7)
|
|
|
1.5
|
%
|
Jerry L. Malis
|
|
|
1,119,745
|
(8)
|
|
|
4.6
|
%
|
Pamela G. Boone
|
|
|
118,355
|
(9)
|
|
|
*
|
|
(ii) All Executive Officers and Directors as a Group
(8 persons)
|
|
|
2,701,896
|
|
|
|
10.9
|
%
|
(iii) Certain Beneficial Owners
|
|
|
|
|
|
|
|
|
Steven R. Becker
|
|
|
1,510,444
|
(10)
|
|
|
6.2
|
%
|
Louis Uchitel
|
|
|
1,593,619
|
(11)
|
|
|
6.5
|
%
|
|
|
|
* |
|
Less than 1%. |
|
(1) |
|
Except as indicated in the footnotes to this table, the persons
named in the table have sole voting and investment power with
respect to all shares of Common Stock shown as beneficially
owned by them. |
7
|
|
|
(2) |
|
Includes 16,000 shares issuable to Mr. Hable subject
to options exercisable currently or within 60 days of
November 17, 2009. |
|
(3) |
|
Includes 24,244 shares owned by Mr. Cardinale and
40,000 shares issuable to Mr. Cardinale subject to
options exercisable currently or within 60 days of
November 17, 2009. |
|
(4) |
|
Includes 3,000 shares owned by Mr. Dick and
100,000 shares issuable to Mr. Dick subject to options
exercisable currently or within 60 days of
November 17, 2009. |
|
(5) |
|
Represents shares held in the Kurt W. Gampp, Jr. Trust. This
does not include 124,225 shares held by Julie Gampp, which
transfer upon death to Mr. Gampp, nor 62 shares held
by his daughter, Lindsey Gampp. Mr. Gampp disclaims
beneficial ownership as to these shares. |
|
(6) |
|
Includes 4,000 shares owned by Mr. Guarch and
40,000 shares issuable to Mr. Guarch subject to
options exercisable currently or within 60 days of
November 17, 2009. |
|
(7) |
|
Includes 326,710 shares held in the Hinshaw-Harrison Joint
Revocable Living Trust. Ms. Hinshaw, in her capacity as
trustee, possesses joint voting and investment power with
respect to these shares. Also includes 40,000 shares
issuable to Ms. Hinshaw subject to options exercisable
currently or within 60 days of November 17, 2009. |
|
(8) |
|
Includes 864,745 owned by Dr. Malis, 200,000 shares
held in the Malis Family L.P., and 55,000 shares issuable
to Dr. Malis subject to options exercisable currently or
within 60 days of November 17, 2009. The Malis Family
L.P. is a limited partnership in which Jerry L. Malis is the
general partner and possesses voting and investment power. |
|
(9) |
|
Includes the following: 65,000 shares jointly owned by
Ms. Boone and her spouse, 32,700 shares issued to
Ms. Boone subject to restrictions, including a cliff
vesting period of five years from the respective dates of the
grants and 20,655 shares issuable to Ms. Boone subject
to options exercisable currently or within 60 days of
November 17, 2009. |
|
(10) |
|
Pursuant to Mr. Beckers Schedule 13G/A filed
with the SEC on October 20, 2009, Mr. Becker has sole
voting and sole dispositive power over 1,510,444 shares.
Mr. Beckers address is 300 Crescent Court,
Suite 1111, Dallas, Texas 75201. |
|
(11) |
|
Pursuant to Mr. Uchitels Schedule 13D/A filed
with the SEC on April 14, 2009, Mr. Uchitel has sole
voting power over 192,221 shares, shared voting power over
538,100 shares, sole dispositive power over
192,221 shares and shared dispositive power over
1,361,398 shares. Mr. Uchitels address is 142
Cedar Road, Elkins Park, Pennsylvania 19027. |
SECTION 16(a)
BENEFICIAL OWNERSHIP REPORTING COMPLIANCE
Section 16(a) of the Exchange Act requires the
Companys directors and executive officers, and persons who
own more than 10% of a registered class of the Companys
equity securities, to file reports of ownership of, and
transactions in, the Companys securities with the SEC and
Nasdaq. Such directors, executive officers and 10% stockholders
are also required to furnish the Company with copies of all
Section 16(a) forms they file.
Based solely upon a review of reports furnished to the Company,
and on written representations from certain reporting persons,
the Company believes that, with respect to the fiscal year ended
July 31, 2009, each director, executive officer and 10%
stockholder of the Companys securities made timely filings
of all reports required by Section 16 of the Exchange Act,
except as follows: Ms. Boone filed a late Form 4 on
November 14, 2008 reporting one transaction, a restricted
stock grant.
8
EXECUTIVE
COMPENSATION
2009
Summary Compensation Table
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All
|
|
|
|
|
Fiscal
|
|
|
|
|
|
Stock
|
|
Option
|
|
Other
|
|
|
Name and Principal Position
|
|
Year
|
|
Salary
|
|
Bonus
|
|
Awards(1)
|
|
Awards(1)
|
|
Compensation
|
|
Total
|
|
David M. Hable(2)
|
|
|
2009
|
|
|
$
|
170,000
|
|
|
|
|
|
|
|
|
|
|
$
|
9,623
|
(3)
|
|
$
|
8,128
|
|
|
$
|
187,751
|
|
President
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Kurt W. Gampp, Jr.
|
|
|
2009
|
|
|
$
|
363,437
|
|
|
$
|
5,000
|
(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
368,437
|
|
Executive Vice
|
|
|
2008
|
|
|
$
|
359,840
|
|
|
$
|
15,795
|
(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
375,635
|
|
President & Chief Operating Officer
|
|
|
2007
|
|
|
$
|
346,000
|
|
|
$
|
5,000
|
(4)
|
|
|
|
|
|
|
|
|
|
$
|
23,248
|
|
|
$
|
374,248
|
|
Jerry L. Malis
|
|
|
2009
|
|
|
$
|
252,252
|
|
|
$
|
5,000
|
(4)
|
|
|
|
|
|
$
|
2,710
|
(5)
|
|
|
|
|
|
$
|
259,962
|
|
Executive Vice
|
|
|
2008
|
|
|
$
|
240,240
|
|
|
$
|
16,574
|
(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
256,814
|
|
President & Chief Scientific Officer
|
|
|
2007
|
|
|
$
|
231,000
|
|
|
$
|
5,000
|
(4)
|
|
|
|
|
|
|
|
|
|
$
|
21,794
|
|
|
$
|
257,794
|
|
Pamela G. Boone
|
|
|
2009
|
|
|
$
|
243,600
|
|
|
$
|
5,000
|
(4)
|
|
$
|
24,280
|
(6)
|
|
$
|
7,507
|
(7)
|
|
|
|
|
|
$
|
280,387
|
|
Executive Vice
|
|
|
2008
|
|
|
$
|
232,000
|
|
|
$
|
18,920
|
(4)
|
|
$
|
15,000
|
(6)
|
|
$
|
7,507
|
(7)
|
|
|
|
|
|
$
|
273,427
|
|
President & Chief Financial Officer
|
|
|
2007
|
|
|
$
|
200,000
|
|
|
$
|
5,000
|
(4)
|
|
$
|
7,000
|
(6)
|
|
$
|
7,518
|
(7)
|
|
$
|
12,994
|
|
|
$
|
232,512
|
|
Lawrence C. Cardinale(8)
|
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
13,096
|
(9)
|
|
$
|
52,200
|
|
|
$
|
65,296
|
|
Former Acting Principal Executive Officer
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
16,231
|
(9)
|
|
$
|
16,750
|
|
|
$
|
32,981
|
|
Independent Director
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
29,502
|
(9)
|
|
$
|
15,750
|
|
|
$
|
45,252
|
|
Robert H. Dick(8)
|
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
13,096
|
(10)
|
|
$
|
86,750
|
|
|
$
|
99,846
|
|
Former Acting Principal Executive Officer
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
16,231
|
(10)
|
|
$
|
16,750
|
|
|
$
|
32,981
|
|
Independent Director
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
29,502
|
(10)
|
|
$
|
15,750
|
|
|
$
|
45,252
|
|
Guy R. Guarch(8)
|
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
13,096
|
(9)
|
|
$
|
46,000
|
|
|
$
|
59,096
|
|
Former Acting Principal Executive Officer
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
16,231
|
(9)
|
|
$
|
13,750
|
|
|
$
|
29,750
|
|
Independent Director
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
29,502
|
(9)
|
|
$
|
7,500
|
|
|
$
|
37,002
|
|
Juanita H. Hinshaw(8)
|
|
|
2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
13,096
|
(9)
|
|
$
|
48,250
|
|
|
$
|
61,346
|
|
Former Acting Principal Executive Officer
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
16,231
|
(9)
|
|
$
|
17,500
|
|
|
$
|
33,731
|
|
Independent Director
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
29,502
|
(9)
|
|
$
|
21,750
|
|
|
$
|
51,252
|
|
|
|
|
(1) |
|
The reported amounts reflect the dollar amount recognized for
financial statement reporting purposes in accordance with
FAS 123R. See Note 13 to the Companys annual
report on
Form 10-K
for the fiscal year ended July 31, 2009 for a discussion of
the assumptions made in the valuation of these awards under
FAS 123R. |
|
(2) |
|
Mr. Hable was appointed the Companys President, Chief
Executive Officer and director on January 29, 2009. |
|
(3) |
|
The option holdings of Mr. Hable include an option to
purchase 48,000 shares of Common Stock granted on
January 29, 2009 at an exercise price of $1.00 per share.
These options expire on January 29, 2019. One twelfth of
these options vested immediately upon the signing of the
employment agreement and the remainder vest proratably over the
next 11 quarters. |
9
|
|
|
(4) |
|
Includes Christmas bonus of $5,000 for each of Mr. Gampp,
Dr. Malis and Ms. Boone plus an amount based upon
their percentage of objectives achieved in the Company-wide
objectives and the functional and personal development
objectives. |
|
(5) |
|
The option holdings of Dr. Malis include an option to
purchase 55,000 shares of Common Stock of which 50,000 were
granted on December 12, 2000 at an exercise price of $1.125
per share and 5,000 were granted on December 12, 2008 at an
exercise price of $0.90 per share. The December 12, 2000
grant expires on December 12, 2010 and is exercisable as of
July 31, 2009. The December 12, 2008 grant expires on
December 12, 2018 and vest proratably over twelve months
from the date of the grant. |
|
(6) |
|
The restricted stock holdings of Ms. Boone include
32,700 shares of which 6,387 were granted on March 7,
2006 at $5.48 per share, vesting on March 7, 2011; 11,050
were granted on August 1, 2007 at $3.62 per share, vesting
on August 1, 2012; and 15,263 were granted on
August 1, 2008 at $3.04 per share on August 1, 2013.
Dividends will be paid on this restricted stock if the Company
grants dividends to its common shareholders. |
|
(7) |
|
The option holdings of Ms. Boone include an option to
purchase 41,310 shares of Common Stock granted on
May 19, 2005 at an exercise price of $1.09 per share. These
options expire on May 19, 2015. Fifty percent of the
options vested on May 19, 2009 and the remaining fifty
percent will vest on May 19, 2010. |
|
(8) |
|
From July 31, 2008 until January 28, 2009, each of our
independent directors served as principal executive officer of
the Company, generally on a weekly rotating basis. |
|
(9) |
|
The option holdings of Mr. Cardinale, Mr. Guarch and
Ms. Hinshaw include an option to purchase
40,000 shares of Common Stock of which 10,000 were granted
on September 22, 2005 at an exercise price of $5.00 per
share which expire on September 22, 2015; 10,000 were
granted on November 30, 2006 at an exercise price of $3.77
per share which expire on November 30, 2016; 10,000 were
granted on December 11, 2007 at an exercise price of $2.95
per share which expire on December 11, 2017; and 10,000
were granted on December 12, 2008 at an exercise price of
$0.90 per share which expire on December 12, 2018. The
options granted on December 12, 2008 vest proratably at the
end of each quarter over a twelve month period. |
|
(10) |
|
The option holdings of Mr. Dick include an option to
purchase 100,000 shares of Common Stock of which 10,000
were granted on December 2, 2000 at an exercise price of
$1.125 per share which expire on December 2, 2010; 10,000
were granted on March 15, 2001 at an exercise price of
$2.75 per share which expire on March 15, 2011; 10,000 were
granted on March 14, 2002 at an exercise price of $2.75 per
share which expire on March 14, 2012; 10,000 were granted
on March 13, 2003 at an exercise price of $1.06 per share
which expires on March 13, 2013; 10,000 were granted on
March 11, 2004 at an exercise price of $1.79 per share
which expire on March 11, 2014; 10,000 were granted on
September 19, 2005 at an exercise price of $4.55 per share
which expire on September 19, 2015; 10,000 were granted on
September 20, 2005 at an exercise price of $5.165 per share
which expire on September 22, 2015; 10,000 were granted on
November 30, 2006 at an exercise price of $3.77 per share
which expire on November 30, 2016; 10,000 were granted on
December 11, 2007 at an exercise price of $2.95 per share
which expire on December 11, 2017; and 10,000 were granted
on December 12, 2008 at an exercise price of $0.90 per
share which expire on December 12, 2018. The options
granted on December 12, 2008 vest proratably at the end of
each quarter over a twelve month period. |
Narrative
to Summary Compensation Table
During the fiscal year 2008, the terms of employment for
Messrs. Gampp and Malis were governed by each of their
employment agreements with the Company entered into in 2005.
Pursuant to the terms of their agreements, Mr. Gampps
initial base salary was $346,000 and Dr. Malis
initial base salary was $230,000; provided that after the first
year of employment, each of their base salaries was determined
by the Compensation Committee, subject to Board approval, and in
no event could be lower than their respective initial base
salaries. In addition, each of them received such other benefits
that the Company provides to its executive officers, including
healthcare, life insurance, disability and 30 days of paid
vacation. Each of Messrs. Gampp and Malis were eligible to
receive an annual bonus as determined in the sole discretion of
the Compensation Committee. Messrs. Gampps and
Malis employment agreements expired on September 21,
2008 according to their terms. The negative covenant provisions
in these agreements survive.
10
Mr. Hable has entered into a change of control agreement
and Ms. Boone has entered an employment agreement, the
terms of which are more fully discussed in the section
EMPLOYMENT AGREEMENTS AND SEVERANCE AGREEMENTS below.
Messrs. Cardinale, Dick and Guarch and Mrs. Hinshaw
received compensation in the fiscal years 2009, 2008 and 2007
which represented director compensation paid pursuant to the
directors compensation program for their attendance at
meetings and for their time spent as the Companys
principal executive officer of the Company, generally on a
weekly rotating basis, from July 31, 2008 through
January 28, 2009. See Director Compensation
above for more information regarding compensation of directors.
2009
Outstanding Equity Awards at Fiscal Year-End
The following table sets forth information on outstanding
options and stock awards held by the named executive officers as
of July 31, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity Incentive
|
|
|
Option Awards
|
|
Equity Incentive
|
|
Plan Awards:
|
|
|
Number of
|
|
Number of
|
|
|
|
|
|
Plan Awards:
|
|
Market or
|
|
|
Securities
|
|
Securities
|
|
|
|
|
|
Number of
|
|
Payout Value of
|
|
|
Underlying
|
|
Underlying
|
|
|
|
|
|
Unearned Shares,
|
|
Unearned Shares,
|
|
|
Unexercised
|
|
Unexercised
|
|
Option
|
|
|
|
Units or Other
|
|
Units or Other
|
|
|
Options
|
|
Options
|
|
Exercise
|
|
Option
|
|
Rights That Have
|
|
Rights That Have
|
|
|
(#)
|
|
(#)
|
|
Price
|
|
Expiration
|
|
Not Vested
|
|
Not Vested
|
Name
|
|
Exercisable
|
|
Unexercisable
|
|
($)
|
|
Date
|
|
(#)
|
|
($)
|
|
Lawrence C. Cardinale
|
|
|
10,000
|
|
|
|
|
|
|
$
|
5.00
|
|
|
|
9/22/15
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
3.77
|
|
|
|
11/30/16
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
2.95
|
|
|
|
12/11/17
|
|
|
|
|
|
|
|
|
|
|
|
|
6,667
|
(1)
|
|
|
3,333
|
(1)
|
|
$
|
0.90
|
|
|
|
12/12/18
|
|
|
|
|
|
|
|
|
|
Robert H. Dick
|
|
|
10,000
|
|
|
|
|
|
|
$
|
1.125
|
|
|
|
12/2/10
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
2.75
|
|
|
|
3/15/11
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
2.75
|
|
|
|
3/14/12
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
1.06
|
|
|
|
3/13/13
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
1.79
|
|
|
|
3/11/14
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
4.55
|
|
|
|
9/19/15
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
5.165
|
|
|
|
9/22/15
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
3.77
|
|
|
|
11/30/16
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
2.95
|
|
|
|
12/11/17
|
|
|
|
|
|
|
|
|
|
|
|
|
6,667
|
(1)
|
|
|
3,333
|
(1)
|
|
$
|
0.90
|
|
|
|
12/12/18
|
|
|
|
|
|
|
|
|
|
Guy R. Guarch
|
|
|
10,000
|
|
|
|
|
|
|
$
|
5.00
|
|
|
|
9/22/15
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
3.77
|
|
|
|
11/30/16
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
2.95
|
|
|
|
12/11/17
|
|
|
|
|
|
|
|
|
|
|
|
|
6,667
|
(1)
|
|
|
3,333
|
(1)
|
|
$
|
0.90
|
|
|
|
12/12/18
|
|
|
|
|
|
|
|
|
|
Juanita H. Hinshaw
|
|
|
10,000
|
|
|
|
|
|
|
$
|
5.00
|
|
|
|
9/22/15
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
3.77
|
|
|
|
11/30/16
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
$
|
2.95
|
|
|
|
12/11/17
|
|
|
|
|
|
|
|
|
|
|
|
|
6,667
|
(1)
|
|
|
3,333
|
(1)
|
|
$
|
0.90
|
|
|
|
12/12/18
|
|
|
|
|
|
|
|
|
|
David M. Hable
|
|
|
12,000
|
(2)
|
|
|
36,000
|
(2)
|
|
$
|
1.00
|
|
|
|
1/19/19
|
|
|
|
|
|
|
|
|
|
Jerry L. Malis
|
|
|
50,000
|
|
|
|
|
|
|
$
|
1.125
|
|
|
|
12/12/10
|
|
|
|
|
|
|
|
|
|
|
|
|
3,750
|
(3)
|
|
|
1,250
|
(3)
|
|
$
|
0.90
|
|
|
|
12/12/18
|
|
|
|
|
|
|
|
|
|
Pamela G. Boone
|
|
|
20,655
|
(4)
|
|
|
20,655
|
(4)
|
|
$
|
1.089
|
|
|
|
5/19/15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,387
|
(5)
|
|
$
|
35,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,050
|
(6)
|
|
$
|
40,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,263
|
(7)
|
|
$
|
46,400
|
|
|
|
|
(1) |
|
Represents an option to purchase 10,000 shares of Common
Stock which vests proratably at the end of each quarter over a
twelve month period beginning on December 12, 2008. |
11
|
|
|
(2) |
|
Represents an option to purchase 48,000 shares of Common
Stock granted on January 29, 2009. One twelfth of this
option vested on January 29, 2009 and the remainder vests
proratably over the next 11 quarters. |
|
(3) |
|
Represents an option to purchase 5,000 shares of Common
Stock which vests proratably at the end of each quarter over a
twelve month period beginning on December 12, 2008. |
|
(4) |
|
Represents an option to purchase 41,310 shares of Common
Stock. Fifty percent of the option vested on May 19, 2009
and the remaining fifty percent will vest on May 19, 2010. |
|
(5) |
|
These shares vest on March 7, 2011. |
|
(6) |
|
These shares vest on August 1, 2012. |
|
(7) |
|
These shares vest on August 1, 2013. |
Mr. Gampp did not have any options to purchase Common Stock
or restricted stock as of July 31, 2009.
EMPLOYMENT
AGREEMENTS AND SEVERANCE AGREEMENTS
Mr. Hable and the Company entered into a change in control
agreement, effective as of January 29, 2009. The change in
control agreement has a rolling one-year term and expires
30 days after Mr. Hables employment is
terminated. Payments to which Mr. Hable is due under the
change in control agreement are not subject to reduction in the
event he receives other compensation for services rendered after
termination of his employment, and he is under no duty to
mitigate any payments.
The change in control agreement provides that if
Mr. Hables employment is terminated within one year
following a change in control for cause or disability (as both
are defined in the change in control agreement), as a result of
his death or by Mr. Hable other than as Involuntary
Termination (as defined in the change in control agreement), the
Company shall pay to Mr. Hable all compensation earned or
accrued through his employment termination date, including
(i) base salary; (ii) reimbursement for reasonable and
necessary expenses; (iii) vacation pay; (iv) bonuses
and incentive compensation; and (v) all other amounts to
which he is entitled under any compensation or benefit plan of
the Company (standard compensation due).
If Mr. Hables employment is terminated within one
year following a change in control without cause and for any
reason other than death or disability, including involuntary
termination, and provided he enters into a separation agreement
within 30 days of his employment termination, he shall
receive the following in a lump sum (early
severance): (i) all standard compensation due;
(ii) an amount equal to one-half times his annual base
salary at the rate in effect immediately prior to the change in
control; and (iii) as compensation for certain lost
benefits, an amount equal to 10% of his base salary at the rate
in effect immediately prior to the change in control. If such
termination occurs during the period that is 6 to 12 months
after Mr. Hables start date (as defined in the change
in control agreement), he shall receive in a lump sum the early
severance and an additional amount equal to the sum of
one-twelfth times his base salary for each month of employment
completed between 7 and 12 months after his start date. If
Mr. Hable is terminated at any time after the first
anniversary of his start date, he shall receive the following
(ordinary severance): (i) all standard
compensation due; (ii) an amount equal to one times his
annual base salary at the rate in effect immediately prior to
the change in control; and (iii) any amount payable as of
the termination date under the Companys objectives-based
incentive plan. Such ordinary severance shall be paid in 12
equal monthly installments beginning in the month following
Mr. Hables employment termination. Furthermore, all
of Mr. Hables awards of shares or options shall
immediately vest and be exercisable for one year after the date
of his involuntary employment termination.
As defined in the change in control agreement, a change in
control means: (i) the acquisition by any person (as
defined in the change in control agreement) of securities of the
Company representing 51% or more of the combined voting power of
the Companys outstanding voting securities; (ii) a
change in the composition of the Board of Directors of the
Company such that during any period of up to two consecutive
years, individuals who constitute members of the Board of
Directors at the beginning of the period cease to constitute the
majority thereof; and (iii) the closing of certain mergers
or consolidations of the Company with any other corporation.
On August 1, 2007, Ms. Boone entered into three-year
employment agreement with the Company. Pursuant to her
agreement, Ms. Boones base salary is $232,000. In
addition, Ms. Boone receives such other benefits that the
12
Company provides to its executive officers, including
healthcare, life insurance, disability and 30 days of paid
vacation. Ms. Boone is eligible to receive an annual bonus,
as may be determined in the sole discretion of the Compensation
Committee of the Companys Board of Directors.
If Ms. Boone is terminated without cause or within twelve
months following a change of control, or if she resigns for good
reason, she shall be entitled to her base salary and health care
benefits for a
15-month
period following termination. As used in the employment
agreement, cause means (1) the executive
officers conviction of any felony, or conviction for
embezzlement or misappropriation of Company money or other
property; (2) any act of gross negligence in performing the
executive officers duties; (3) the executive
officers willful refusal to execute her duties (other than
for disability); or (4) the executive officers breach
of the non-competition terms contained in her employment
agreement. Termination for the events described in
clauses (2) and (3) above will not constitute
termination for cause unless the executive officer
is provided written notice reasonably detailing such occurrence
and is given five business days after receipt of such notice to
cure such event and an opportunity to be heard before the
Companys Board of Directors.
As used in the employment agreement with Ms. Boone, the
term good reason means (1) failure to pay, or a
reduction, by the Company of the executive officers base
salary; (2) the failure or refusal by the Company to
provide the executive officer with the benefits set forth in her
employment agreement; (3) the assignment to the executive
officer of any duties materially inconsistent with the duties
set forth in the employment agreement, which assignment is not
cured within five business days of written notice to the
Company; (4) a requirement imposed by the Company on
Ms. Boone that results in her being based at a location
that is outside a
35-mile
radius from the Companys current corporate offices in
OFallon, Missouri; (5) a change in the executive
officers title; (6) any material breach by the
Company of the employment agreement, which breach is not cured
within five business days after receipt of written notice from
the executive officer; or (7) the termination of the
executive officers employment other than for cause, death
or disability.
Change of control is defined in Ms. Boones employment
agreement to mean a change in the ownership or effective control
of the Company, or a change in the ownership of a substantial
portion of the Company.
The employment agreement for Ms. Boone contains
non-competition covenants, depending on the circumstances of any
termination of employment, and non-solicitation provisions. No
payments upon termination or resignation as described above
shall be received upon her breach of the non-competition and
non-solicitation provisions of her employment agreement.
Furthermore, Ms. Boone is subject to an agreement that any
products, inventions, discoveries and improvements made by her
during the employment term shall be the property of the Company.
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Since the late 1960s, the late Dr. Leonard Malis, one
of Valley Forges former directors, on an individual basis
has been a party to consulting and other agreements with
Codman & Shurtleff, Inc., the Companys principal
customer. Since 1983, Dr. Leonard Malis has been a party to
an agreement with Codman under which Dr. Leonard Malis
received royalty payments for the use of the
Malis®
trademark on certain products sold by Codman to end users,
including products Valley Forge sold to Codman. Dr. Leonard
Malis developed neurosurgical instruments for Codman with no
pecuniary benefits to Valley Forge. On October 22, 2004,
Valley Forge entered into an option agreement with
Dr. Leonard Malis under which Valley Forge was granted an
option to acquire the
Malis®
trademark from Dr. Leonard Malis at any time over a period
of five years.
On October 12, 2005, the Company exercised its option with
respect to the
Malis®
trademark. We paid the estate of Dr. Leonard I. Malis
$159,904 in cash and the remainder in a $3,997,600 promissory
note which will be paid in 25 equal quarterly installments of
$159,904. The Company has made four quarterly payments on this
note during each of the years ended July 31, 2009 and 2008.
In addition, the Company has made one quarterly payment and
intends to make three additional quarterly payments during the
fiscal year ending July 31, 2010. The promissory note is
secured by a security interest in the trademark and our
DualWavetm
patents.
13
PROPOSAL 2
RATIFICATION OF THE APPOINTMENT OF THE COMPANYS
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The firm of UHY LLP (UHY) acts as our principal
independent registered public accounting firm. UHY LLP personnel
work under the direct control of UHY LLP partners and are leased
from wholly-owned subsidiaries of UHY Advisors, Inc. in an
alternative practice structure.
The following table shows fees billed for professional services
rendered by UHY for fiscal 2008 and fiscal 2009:
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year Ended
|
|
|
Fiscal Year Ended
|
|
|
|
July 31, 2009
|
|
|
July 31, 2008
|
|
|
Audit Fees(1)
|
|
$
|
251,188
|
|
|
$
|
282,206
|
|
Audit-Related Fees(2)
|
|
|
9,629
|
|
|
|
10,150
|
|
Tax Fees(3)
|
|
|
3,618
|
|
|
|
|
|
All Other Fees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
264,435
|
|
|
$
|
292,356
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Audit Fees for the fiscal years ended July 31, 2009 and
2008 represent fees for services for the audit of the
consolidated financial statements, the review of the quarterly
financial statements and consultation concerning financial
accounting and reporting standards. Fees in 2008 included an
audit of the Companys internal control over financial
reporting. |
|
(2) |
|
Audit-Related Fees for the fiscal years ended July 31, 2009
and 2008 represent fees for services for the audit of the
Synergetics, Inc. Incentive Savings Plan. |
|
(3) |
|
Tax Fees are comprised of fees relating to the preparation of
Form 5500. |
Pursuant to the Audit Committees charter, all audit and
permissible non-audit services provided by the independent
registered public accounting firm must be pre-approved. These
services may include audit services, audit-related services, tax
services and other services. Pre-approval is generally provided
for up to one year and any pre-approval is detailed as to the
particular service or category of service. The independent
registered public accounting firm and management are required to
periodically report to the Audit Committee regarding the extent
of services provided by the independent registered public
accounting firm in accordance with the policies set forth in the
Audit Committee charter. Consistent with the Audit
Committees policy, all audit and permissible non-audit
services provided by UHY during the fiscal years ended
July 31, 2009 and 2008 were pre-approved by the Audit
Committee.
In considering the nature of the services provided by the
independent registered public accounting firm for the fiscal
year ended July 31, 2009, the Audit Committee determined
that such services are compatible with the provision of
independent audit services. The Audit Committee discussed these
services with the independent registered public accounting firm
and management for the fiscal year ended July 31, 2009 to
determine that they are permitted under the rules and
regulations concerning auditors independence promulgated
by the SEC to implement the Sarbanes-Oxley Act of 2002, as well
as rules of the American Institute of Certified Public
Accountants.
UHY acted as the Companys independent registered public
accounting firm for the 2009 fiscal year. The Audit Committee
selected UHY to act as the Companys independent registered
public accounting firm for the 2010 fiscal year. UHY
representatives are expected to attend the Annual Meeting. They
will have an opportunity to make a statement if they desire to
do so and will be available to respond to appropriate questions.
The Company is asking its stockholders to ratify the selection
of UHY as the Companys independent registered public
accounting firm. Although ratification is not required by our
bylaws or otherwise, the Board is submitting the selection of
UHY to our stockholders for ratification as a matter of good
corporate practice. If the selection is not ratified, the Audit
Committee will consider whether it is appropriate to select
another independent registered public accounting firm. Even if
the selection is ratified, the Audit Committee in its discretion
may select a different independent registered public accounting
firm at any time during the fiscal year if it determines that
such a change would be in the best interests of the Company and
its stockholders.
14
THE BOARD
OF DIRECTORS RECOMMENDS A VOTE FOR RATIFICATION OF
THE APPOINTMENT OF THE COMPANYS INDEPENDENT REGISTERED
PUBLIC
ACCOUNTING FIRM
REPORT OF
THE AUDIT COMMITTEE
The Audit Committee (the Committee) oversees the
Companys financial reporting process on behalf of the
Board of Directors. Management has the primary responsibility
for the financial statements and the reporting process,
including internal control systems. The Companys
independent registered public accounting firm is responsible for
expressing an opinion on the conformity of the Companys
audited financial statements with U.S. generally accepted
accounting principles.
In fulfilling its oversight responsibilities, the Committee
reviewed and discussed with management the audited financial
statements in the Annual Report on
Form 10-K
for the year ended July 31, 2009, including a discussion of
the accounting principles, the reasonableness of significant
judgments and the clarity of disclosures in the financial
statements.
In addition, the Committee discussed with the independent
registered public accounting firm the matters required to be
discussed by the Statement on Auditing Standards No. 61, as
amended, as adopted by the Public Company Accounting Oversight
Board in Rule 3200T. The Committee met with the independent
registered public accounting firm, with and without management
present, to discuss the results of their examinationsand the
overall quality of the Companys financial reporting. In
addition, the Audit Committee has reviewed and discussed with
management and UHY LLP managements report on internal
control over financial reporting in accordance with
Section 404 of the Sarbanes-Oxley Act of 2002.
The Committee has received the written disclosures and the
letter from the independent registered public accounting firm
required by applicable requirements of the Public Company
Accounting Oversight Board regarding the independent registered
public accounting firms communications with the Committee
concerning independence, and has discussed with the independent
registered public accounting firm the independent registered
public accounting firms independence.
In reliance on the reviews and discussions referred to above,
the Committee recommended to the Board of Directors (and the
Board has approved) that the audited financial statements be
included in the Annual Report on
Form 10-K
for the year ended July 31, 2009, filed with the SEC.
Submitted by the Audit Committee of the Board of Directors.
Juanita H. Hinshaw (Chairperson)
Lawrence C. Cardinale
Robert H. Dick
OTHER
MATTERS
Management does not know of any other business that may be
considered at the Annual Meeting. However, if any matters other
than those referred to above should properly come before the
Annual Meeting, it is the intention of the persons named in the
accompanying form of proxy to vote the proxies held by them in
accordance with their best judgment.
The Company will bear the costs of its solicitation of proxies.
In addition to the use of the mails, proxies may be solicited by
electronic mail, personal interview, telephone, telegram and
telefax by the directors, officers and employees of the Company.
Arrangements will also be made with brokerage houses and other
custodians, nominees and fiduciaries for the forwarding of
solicitation material to the beneficial owners of stock held of
record by such persons, and the Company may reimburse such
custodians, nominees and fiduciaries for reasonable
out-of-pocket expenses incurred by them in connection therewith.
15
FORM 10-K
Along with mailing the proxy materials, we have included a copy
of our Annual Report on
Form 10-K
for the fiscal year ended July 31, 2009. We will provide
stockholders with additional copies of our Annual Report on
Form 10-K
for the fiscal year ended July 31, 2009, without charge,
upon written request to Pamela G. Boone, Secretary, Synergetics
USA, Inc., 3845 Corporate Centre Drive, OFallon, Missouri
63368.
HOUSEHOLDING
OF PROXY MATERIALS
The SEC has adopted rules that permit companies and
intermediaries (e.g. brokers) to satisfy the delivery
requirements for proxy statements and annual reports with
respect to two or more stockholders sharing the same address by
delivering a single proxy statement and annual report addressed
to those stockholders. This process, which is commonly referred
to as householding, potentially means extra
convenience for stockholders and cost savings for companies.
A number of brokers with accountholders who are stockholders
will be householding our proxy materials. As indicated in the
notice previously provided by these brokers to stockholders, a
single proxy statement and annual report will be delivered to
multiple stockholders sharing an address unless contrary
instructions have been received from an affected stockholder.
Once you have received notice from your broker or us that they
will be householding communications to your address,
householding will continue until you are notified otherwise.
Stockholders who currently receive multiple copies of the proxy
materials at their address and would like to request
householding of their communications should contact their broker
or, if a stockholder is a direct holder of shares of our Common
Stock, they should submit a written request to our transfer
agent, American Stock Transfer & Trust Company,
6201 15th Avenue, Brooklyn, New York 11219.
To delist yourself from householding in the future you may write
the Company at 3845 Corporate Centre Drive, OFallon,
Missouri 63368, Attention: Pamela G. Boone or call
(636) 939-5100.
Upon written or oral request directed to the Company at the
address or phone number listed above, we will deliver promptly a
separate copy of the proxy materials.
STOCKHOLDER
PROPOSALS FOR 2010 ANNUAL MEETING OF STOCKHOLDERS
Stockholder proposals submitted for inclusion in the proxy
statement and form of proxy for the 2010 Annual Meeting of
Stockholders must be received at the corporate offices of the
Company, addressed to the attention of Ms. Pamela G. Boone,
Secretary, Synergetics USA, Inc. no later than July 27,
2010. The proposals must comply with the rules of the SEC
relating to stockholder proposals. The Companys Bylaws
provide that no business may be brought before an annual meeting
unless specified in the notice of meeting, brought before the
meeting by or at the direction of the Board of Directors, or
otherwise brought by a stockholder who has delivered notice to
the Company (containing certain information specified in the
Bylaws) not less than 60 or more than 90 days before the
anniversary date of the immediately preceding annual meeting of
stockholders. Therefore, for the 2010 Annual Meeting of
Stockholders, such notice must be delivered no earlier than
September 18, 2010 and no later than October 18, 2010.
A copy of the full text of these Bylaw provisions may be
obtained by writing to the Secretary at the address indicated
above.
By Order of the Board of Directors,
PAMELA G. BOONE
Secretary
November 24, 2009
16
0 SYNERGETICS USA, INC. PROXY SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF SYNERGETICS USA,
INC. FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 17, 2009 The undersigned, having
received the notice and accompanying Proxy Statement for said meeting, hereby appoints Pamela G.
Boone and Peter T. Rasche, and each of them, with full power of substitution, as the undersigneds
proxies and attorneys-in-fact to vote at the Annual Meeting of Stockholders of Synergetics USA,
Inc. (the Company) to be held on December 17, 2009 (the Annual Meeting), or at any adjournment
thereof, all shares of voting stock of the Company which the undersigned may be entitled to vote.
The above proxies are hereby instructed to vote as shown on the reverse of this card and in their
discretion upon such other business as may properly come before the Annual Meeting or at any
adjournment or postponement thereof. (Continued and to be signed on the reverse side.) 14475 |
ANNUAL MEETING OF STOCKHOLDERS OF SYNERGETICS USA, INC. December 17, 2009 NOTICE OF INTERNET
AVAILABILITY OF PROXY MATERIAL: The Notice of Meeting, proxy statement and proxy card are available
at http://www.amstock.com/ProxyServices/ViewMaterial.asp?CoNumber=06536 Please sign, date and mail
your proxy card in the envelope provided as soon as possible. Please detach along perforated line
and mail in the envelope provided. 20230000000000001000 9 121709 The Board of Directors recommends
a vote FOR all director nominees, Proposal 1 and Proposal 2. Signature of Stockholder Date:
Signature of Stockholder Date: To change the address on your account, please check the box at right
and indicate your new address in the address space above. Please note that changes to the
registered name(s) on the account may not be submitted via this method. 1. Election of Directors:
Robert H. Dick Juanita H. Hinshaw 2. Ratification of the appointment of UHY LLP as independent
registered public accounting firm This proxy, when properly executed, will be voted in the manner
directed herein by the undersigned stockholder. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED
FOR ALL PROPOSALS. PLEASE SIGN, DATE AND RETURN THIS PROXY PROMPTLY USING THE ENCLOSED ENVELOPE
EVEN IF YOU PLAN TO ATTEND THE MEETING. FOR ALL NOMINEES WITHHOLD AUTHORITY FOR ALL NOMINEES FOR
ALL EXCEPT (See instructions below) INSTRUCTIONS: To withhold authority to vote for any individual
nominee(s), mark FOR ALL EXCEPT and fill in the circle next to each nominee you wish to withhold,
as shown here: NOMINEES: PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE
MARK YOUR VOTE IN BLUE OR BLACK INK AS SHOWN HERE x MARK X HERE IF YOU PLAN TO ATTEND THE
MEETING. FOR AGAINST ABSTAIN Note: Please sign exactly as your name or names appear on this Proxy.
When shares are held jointly, each holder should sign. When signing as executor, administrator,
attorney, trustee or guardian, please give full title as such. If the signer is a corporation,
please sign full corporate name by duly authorized officer, giving full title as such. If signer is
a partnership, please sign in partnership name by authorized person. |